Sanjivani College of Pharmaceutical Education & Research Ahmednagar Courses & Fees 2025
Sanjivani College of Pharmaceutical Education & Research Ahmednagar Fees & Eligibility
Sanjivani College of Pharmaceutical Education & Research Ahmednagar has released the fees for the academic year 2021-2022. Sanjivani College of Pharmaceutical Education & Research Ahmednagar UG Fees in year 2021 is Rs 7.17 Lakhs. Sanjivani College of Pharmaceutical Education & Research Ahmednagar PG Fees in year 2021 is Rs 3.61 Lakhs.
Sanjivani College of Pharmaceutical Education & Research Ahmednagar top courses include M.Pharm, Diploma in Pharmacy [D.Pharm], B.Pharm. Sanjivani College of Pharmaceutical Education & Research Ahmednagar M.Pharm Fees in year 2020 is Rs 3.61 Lakhs, Diploma in Pharmacy [D.Pharm] Fees is Rs 1.43 Lakhs, B.Pharm Fees is Rs 7.17 Lakhs for entire course duration.
| Course | Fees | Eligibility | Application Date | Action |
|---|---|---|---|---|
M.Pharm 4 Courses | ₹1.8 Lakhs (1st Year Fees) | B.Pharm. + GPAT | - | |
| ₹71,480 (1st Year Fees) | HSC (Science) | - | ||
| ₹1.79 Lakhs (1st Year Fees) | 10+2 + MHT CET/NEET | 16 Jan - 01 Mar 2024 |
Do you think the Course details are wrong ? Report Here
Courses Offered By Sanjivani College of Pharmaceutical Education & Research Ahmednagar 2025
Select Degree and Streams to See Course Fees and Admission Details.
Eligibility:
Application Date:
Eligibility:
Eligibility:
Do you think the fees are wrong ? Report Here
Course Finder
Search from 20K+ Courses and 35+ Streams
Popular Streams:
Sanjivani College of Pharmaceutical Education & Research Ahmednagar Latest News
SPPU and Drone Acharya to Offer Drone Technology Courses; Check Details Here
.jpeg?h=78&w=78&mode=stretch)
SPPU Begins Admissions for More Than 300 Certificate Courses for 2022 Session; Read Details Here
Discover More Colleges
.jpeg?h=72&w=72&mode=stretch)
![RJS College of Pharmacy - [RJSCOP]](https://assets.collegedunia.com/public/college_data/images/logos/1603343683logosolidwhite.png?h=72&w=72&mode=stretch)
SUBSCRIBE TO OUR NEWS LETTER
Comments